UNITAID is in advanced negotiations with Merck & Co., Gilead Sciences and Johnson & Johnson subsidiary Tibotec about licensing their AIDS treatments to generic-drug makers in developing nations, through a patent pool. The health-funding agency singled out 19 drugs from nine companies for possible inclusion in the pool.

Full Story:

Related Summaries